3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
8
Gastrointestinal
1
Conditions
Colorectal Neoplasms
492
Pancreatic Neoplasms
387
Carcinoma, Hepatocellular
261
Colonic Neoplasms
214
Stomach Neoplasms
200
Rectal Neoplasms
190
Esophageal Neoplasms
157
Neoplasms
139
Carcinoma, Non-Small-Cell Lung
133
Liver Neoplasms
129
Neoplasm Metastasis
124
Breast Neoplasms
102
Cholangiocarcinoma
94
Melanoma
85
Ovarian Neoplasms
79
Lung Neoplasms
72
Squamous Cell Carcinoma of Head and Neck
57
Carcinoma, Renal Cell
57
Gastrointestinal Neoplasms
55
Sarcoma
46
Biliary Tract Neoplasms
39
Prostatic Neoplasms
36
Head and Neck Neoplasms
36
Esophageal Squamous Cell Carcinoma
36
Adenocarcinoma Of Esophagus
36
Urinary Bladder Neoplasms
33
Adenocarcinoma
33
Uterine Cervical Neoplasms
31
Triple Negative Breast Neoplasms
31
Gastrointestinal Stromal Tumors
31
Interventions
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
HER2-positive Breast Cancer
×
Gastrointestinal
×
Clear all
NCT05555251
2024-12-16
CONTRAST
BioInvent International AB
Phase 1/2
Terminated
18 enrolled